Medicare Advantage pay to jump as enrollment grows
Published by McKnight’s LTC News
Medicare Advantage plans will receive a 3.4% uptick in federal payments in 2019. That’s nearly 90% more than the 1.84% increase proposed in February.
Notice of the bigger raise came in the Centers for Medicare & Medicaid Services’ 2019 final rate notice and call letter released in April. As many as one-third of Medicare beneficiaries were enrolled in a managed care plan last year, with enrollment running about 7% higher this year, according to Bloomberg Intelligence.
The 2019 revisions include several policies designed to lower drug costs, an effort lauded by Alan Rosenbloom, president and CEO of the Senior Care Pharmacy Coalition.
“Based on preliminary review of more than 1,000 pages of new regulation and guidance, the Senior Care Pharmacy Coalition appreciates CMS’ sensitivity to the characteristics of the long-term care patient population in finalizing new Part D regulations and the 2019 Call Letter,” said Rosenbloom. “We are particularly gratified that the agency modified opioid control provisions based on the unique characteristics of long-term care patients and the heightened controls that long-term care pharmacies provide.”
Rosenbloom continued to press for scrutiny of how Part D plans and their affiliated pharmacy benefits managers impose “inappropriate” fees on long-term care pharmacies.
“We look forward to the Trump administration’s anticipated plan to respond to high drug prices,” he added.
Plans will be able to add generic drugs to their formularies at any time during the year, and increase the number of plan options available.
Senior Care Pharmacy Coalition Applauds Chairman Comer and House Oversight Committee for Shedding Light on Harmful PBM Practices, Encourages Congress to Advance PBM Reform Legislation Heard Today in House Energy and Commerce Committee Health Subcommittee
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy community, released a statement today regarding the House Oversight Committee’s hearing on pharmacy benefit managers.
Stuck in the middle, LTC pharmacies could be dangerously squeezed by drug price negotiations
Any lower drug prices that result from White House efforts to negotiate on behalf of Medicare beneficiaries may lead to short-term gains for nursing homes, but there also could be a steep price to pay in the long-term, experts warned this week. The Centers for Medicare & Medicaid Services on Tuesday announced the first 10 drugs covered by Medicare Part D that will be included in negotiations running through 2024. They are all commonly prescribed drugs that treat conditions ranging from diabetes to arthritis and heart failure.
Biden’s Plans to Reduce Cost of Medicare Drugs To Send Ripple Effects Through Nursing Home Industry
Following the Biden Administration’s bid this week to reduce the price of certain drugs – many of which are commonly used in nursing homes – experts are cautioning that the changes may negatively impact the bottomline of organizations in the sector. As Medicare Part D price negotiations for these drugs come into focus this week, the Senior Care Pharmacy Coalition (SCPC), for one, is warning that changes to Part D might cause “collateral damage” to long-term care pharmacies, the patients they serve and operator partners.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.